Abstract
FIU inventors have discovered a method for detecting
degenerative diseases in humans without a focus on blood factors and, instead,
using protein SAB (or SH3BP5). SAB is a scaffold protein that coordinates
signaling components on the outer mitochondrial membrane, which can drive
processes such as mitochondrial dysfunction and cell death. Using SAB as a
biomarker to organize signaling components and destabilize the integrity of the
mitochondrial membrane potential reduces metabolic efficiency and recruits
death inducing proteins to the mitochondrial surface. Current clinical screens
for degenerative diseases exist at the genetic level. However, using a protein
marker in the blood or tissue for the same purpose would be faster, less
expensive, and in the case of cancer susceptibility to treatment, using SAB could be an earlier biomarker than those previously used.
Benefit
Using SAB as a protein biomarker is faster and less expensive SAB may be an earlier biomarker than other proteins when used for cancer susceptibility to treatment
Market Application
Selective detection of SAB can provide medical insight into the development and progression of human diseases, such as Parkinson, Diabetes, Muscular Dystrophy, Alzheimer, Anyotrophic Lateral Sclerosis, and more
Brochure
